Alnylam Cash Per Share vs Free Cash Flow Analysis

ALNY Stock

USD 256.45 8.44 3.19%

Alnylam Pharmaceuticals financial indicator trend analysis is way more than just evaluating Alnylam Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alnylam Pharmaceuticals is a good investment. Please check the relationship between Alnylam Pharmaceuticals Cash Per Share and its Free Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Cash Per Share vs Free Cash Flow

Cash Per Share vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alnylam Pharmaceuticals Cash Per Share account and Free Cash Flow. At this time, the significance of the direction appears to have no relationship.

The correlation between Alnylam Pharmaceuticals' Cash Per Share and Free Cash Flow is 0.01. Overlapping area represents the amount of variation of Cash Per Share that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Alnylam Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Alnylam Pharmaceuticals' Cash Per Share and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Per Share of Alnylam Pharmaceuticals are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Cash Per Share i.e., Alnylam Pharmaceuticals' Cash Per Share and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.01

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Cash Per Share

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Alnylam Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.Selling General Administrative is likely to rise to about 1 B in 2025, despite the fact that Tax Provision is likely to grow to (94.3 M).

	2022	2023	2024	2025 (projected)
Gross Profit	868.6M	1.5B	1.9B	2.0B
Total Revenue	1.0B	1.8B	2.2B	2.4B

Gross Profit Total Revenue

Alnylam Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Short Long Term Debt Total	Other Liab	Current Deferred Revenue	Long Term Debt	Other Stockholder Equity
Total Assets		0.9	0.94	-0.15	0.94	0.39	-0.98	0.89	0.29	0.93	-0.08	0.76	0.98	0.79	0.97	0.9	0.36	0.93	0.97	0.99	0.96	0.78	0.67	0.26	0.88	0.47
Other Current Liab	0.9		0.85	-0.45	0.82	0.44	-0.93	0.82	-0.01	0.82	-0.11	0.75	0.86	0.54	0.87	0.95	0.21	0.95	0.94	0.9	0.88	0.82	0.53	-0.01	0.94	0.1
Total Current Liabilities	0.94	0.85		-0.19	0.96	0.42	-0.92	0.81	0.13	0.95	0.02	0.64	0.88	0.71	0.93	0.84	0.43	0.89	0.94	0.9	0.94	0.71	0.76	0.5	0.8	0.42
Total Stockholder Equity	-0.15	-0.45	-0.19		-0.18	-0.63	0.29	-0.15	0.38	-0.17	0.17	-0.26	-0.05	0.19	-0.15	-0.56	0.03	-0.49	-0.33	-0.13	-0.19	-0.56	-0.2	0.33	-0.55	0.26
Property Plant And Equipment Net	0.94	0.82	0.96	-0.18		0.51	-0.95	0.87	0.21	0.96	-0.05	0.67	0.88	0.77	0.95	0.86	0.44	0.9	0.95	0.9	0.98	0.75	0.71	0.43	0.83	0.58
Net Debt	0.39	0.44	0.42	-0.63	0.51		-0.52	0.32	-0.12	0.46	-0.41	0.44	0.3	0.28	0.48	0.6	0.2	0.57	0.54	0.35	0.46	0.78	0.34	0.09	0.58	0.42
Retained Earnings	-0.98	-0.93	-0.92	0.29	-0.95	-0.52		-0.91	-0.21	-0.92	0.15	-0.78	-0.94	-0.77	-0.96	-0.95	-0.3	-0.96	-0.99	-0.96	-0.98	-0.85	-0.65	-0.18	-0.94	-0.46
Accounts Payable	0.89	0.82	0.81	-0.15	0.87	0.32	-0.91		0.16	0.84	0.03	0.87	0.87	0.75	0.87	0.82	0.22	0.84	0.88	0.88	0.92	0.64	0.6	0.1	0.84	0.42
Cash	0.29	-0.01	0.13	0.38	0.21	-0.12	-0.21	0.16		0.12	-0.36	0.04	0.39	0.51	0.15	0.11	0.0	0.11	0.12	0.34	0.14	0.21	0.23	0.16	0.11	0.65
Non Current Assets Total	0.93	0.82	0.95	-0.17	0.96	0.46	-0.92	0.84	0.12		0.11	0.66	0.85	0.73	0.92	0.83	0.6	0.88	0.94	0.87	0.95	0.69	0.62	0.43	0.77	0.5
Non Currrent Assets Other	-0.08	-0.11	0.02	0.17	-0.05	-0.41	0.15	0.03	-0.36	0.11		-0.08	-0.15	-0.1	-0.07	-0.19	0.4	-0.13	-0.11	-0.15	-0.06	-0.48	-0.04	0.21	-0.24	-0.24
Other Assets	0.76	0.75	0.64	-0.26	0.67	0.44	-0.78	0.87	0.04	0.66	-0.08		0.75	0.6	0.74	0.75	0.03	0.76	0.75	0.76	0.73	0.67	0.49	-0.07	0.81	0.26
Cash And Short Term Investments	0.98	0.86	0.88	-0.05	0.88	0.3	-0.94	0.87	0.39	0.85	-0.15	0.75		0.8	0.94	0.85	0.24	0.88	0.92	1.0	0.91	0.75	0.66	0.21	0.85	0.46
Common Stock Shares Outstanding	0.79	0.54	0.71	0.19	0.77	0.28	-0.77	0.75	0.51	0.73	-0.1	0.6	0.8		0.75	0.59	0.32	0.63	0.71	0.78	0.76	0.57	0.53	0.39	0.58	0.71
Short Term Investments	0.97	0.87	0.93	-0.15	0.95	0.48	-0.96	0.87	0.15	0.92	-0.07	0.74	0.94	0.75		0.87	0.36	0.91	0.96	0.95	0.97	0.76	0.7	0.3	0.85	0.47
Non Current Liabilities Total	0.9	0.95	0.84	-0.56	0.86	0.6	-0.95	0.82	0.11	0.83	-0.19	0.75	0.85	0.59	0.87		0.23	0.99	0.94	0.89	0.88	0.91	0.61	0.03	0.99	0.29
Other Current Assets	0.36	0.21	0.43	0.03	0.44	0.2	-0.3	0.22	0.0	0.6	0.4	0.03	0.24	0.32	0.36	0.23		0.3	0.38	0.25	0.37	0.15	0.17	0.47	0.1	0.34
Total Liab	0.93	0.95	0.89	-0.49	0.9	0.57	-0.96	0.84	0.11	0.88	-0.13	0.76	0.88	0.63	0.91	0.99	0.3		0.97	0.92	0.91	0.89	0.67	0.11	0.97	0.32
Property Plant And Equipment Gross	0.97	0.94	0.94	-0.33	0.95	0.54	-0.99	0.88	0.12	0.94	-0.11	0.75	0.92	0.71	0.96	0.94	0.38	0.97		0.94	0.98	0.85	0.67	0.22	0.92	0.4
Total Current Assets	0.99	0.9	0.9	-0.13	0.9	0.35	-0.96	0.88	0.34	0.87	-0.15	0.76	1.0	0.78	0.95	0.89	0.25	0.92	0.94		0.93	0.78	0.67	0.19	0.89	0.44
Property Plant Equipment	0.96	0.88	0.94	-0.19	0.98	0.46	-0.98	0.92	0.14	0.95	-0.06	0.73	0.91	0.76	0.97	0.88	0.37	0.91	0.98	0.93		0.75	0.67	0.3	0.86	0.48
Short Long Term Debt Total	0.78	0.82	0.71	-0.56	0.75	0.78	-0.85	0.64	0.21	0.69	-0.48	0.67	0.75	0.57	0.76	0.91	0.15	0.89	0.85	0.78	0.75		0.52	0.01	0.9	0.4
Other Liab	0.67	0.53	0.76	-0.2	0.71	0.34	-0.65	0.6	0.23	0.62	-0.04	0.49	0.66	0.53	0.7	0.61	0.17	0.67	0.67	0.67	0.67	0.52		0.48	0.61	0.43
Current Deferred Revenue	0.26	-0.01	0.5	0.33	0.43	0.09	-0.18	0.1	0.16	0.43	0.21	-0.07	0.21	0.39	0.3	0.03	0.47	0.11	0.22	0.19	0.3	0.01	0.48		-0.04	0.49
Long Term Debt	0.88	0.94	0.8	-0.55	0.83	0.58	-0.94	0.84	0.11	0.77	-0.24	0.81	0.85	0.58	0.85	0.99	0.1	0.97	0.92	0.89	0.86	0.9	0.61	-0.04		0.26
Other Stockholder Equity	0.47	0.1	0.42	0.26	0.58	0.42	-0.46	0.42	0.65	0.5	-0.24	0.26	0.46	0.71	0.47	0.29	0.34	0.32	0.4	0.44	0.48	0.4	0.43	0.49	0.26

Click cells to compare fundamentals

Alnylam Pharmaceuticals Account Relationship Matchups

Alnylam Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	3.4B	3.6B	3.5B	3.8B	4.2B	4.5B
Other Current Liab	355.9M	395.2M	545.5M	713.0M	1.0B	1.1B
Total Current Liabilities	1.1B	1.2B	767.9M	967.8M	1.2B	1.2B
Total Stockholder Equity	1.0B	588.2M	(158.2M)	(220.6M)	67.1M	63.7M
Property Plant And Equipment Net	706.5M	733.6M	738.6M	725.8M	693.9M	728.6M
Net Debt	24.6M	177.6M	453.9M	1.9B	(127.1M)	(133.5M)
Retained Earnings	(4.6B)	(5.4B)	(6.6B)	(7.0B)	(7.3B)	(6.9B)
Accounts Payable	52.0M	73.4M	98.1M	55.5M	88.4M	92.8M
Cash	496.6M	820.0M	866.4M	812.7M	127.1M	120.8M
Non Current Assets Total	1.2B	774.5M	854.1M	847.2M	944.7M	991.9M
Non Currrent Assets Other	500M	40.9M	115.5M	(576.4M)	133.9M	140.6M
Other Assets	32.9M	40.7M	101.1M	115.5M	132.8M	139.4M
Cash And Short Term Investments	1.9B	2.4B	2.2B	2.4B	2.7B	2.8B
Common Stock Shares Outstanding	115.0M	118.5M	121.7M	124.9M	128.6M	73.5M
Short Term Investments	1.4B	1.6B	1.3B	1.6B	1.7B	1.8B
Liabilities And Stockholders Equity	3.4B	3.6B	3.5B	3.8B	4.2B	4.5B
Non Current Liabilities Total	1.3B	1.9B	2.9B	3.1B	3.0B	3.1B
Other Current Assets	625.5M	88.1M	132.9M	126.4M	117.0M	96.0M
Total Liab	2.4B	3.1B	3.7B	4.1B	4.2B	4.4B
Property Plant And Equipment Gross	706.5M	733.6M	738.6M	948.9M	964.3M	1.0B
Total Current Assets	2.2B	2.9B	2.7B	3.0B	3.3B	3.5B
Accumulated Other Comprehensive Income	(43.6M)	(33.3M)	(44.7M)	(23.4M)	(21.0M)	(20.0M)
Property Plant Equipment	425.2M	465.0M	502.0M	523.5M	602.0M	632.1M
Short Long Term Debt Total	521.2M	997.6M	1.3B	2.7B	1.3B	1.4B
Other Liab	327.7M	352.3M	1.4B	406.4M	467.3M	490.7M
Current Deferred Revenue	352.3M	301.8M	42.1M	102.8M	55.5M	52.7M
Other Stockholder Equity	5.6B	6.1B	6.5B	6.8B	65.8M	62.5M
Short Term Debt	50.2M	77.6M	82.3M	96.5M	41.9M	42.6M
Net Receivables	102.4M	198.6M	238.0M	327.8M	405.3M	425.6M
Common Stock Total Equity	1.1M	1.2M	1.2M	1.2M	1.4M	770.9K
Common Stock	1.2M	1.2M	1.2M	1.3M	1.3M	831.2K
Net Tangible Assets	1.4B	1.0B	588.2M	(158.2M)	(182.0M)	(172.9M)
Retained Earnings Total Equity	(3.7B)	(4.6B)	(5.4B)	(6.6B)	(5.9B)	(5.6B)
Capital Surpluse	5.2B	5.6B	6.1B	6.5B	7.4B	7.8B
Inventory	92.3M	122.7M	129.0M	89.1M	78.5M	82.4M
Non Current Liabilities Other	1.6B	1.7B	1.5B	1.6B	1.7B	1.8B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alnylam Cash Per Share vs Free Cash Flow Analysis

Cash Per Share vs Free Cash Flow

Cash Per Share vs Free Cash Flow Correlation Analysis

Correlation Coefficient

Cash Per Share

Free Cash Flow

Alnylam Pharmaceuticals fundamental ratios Correlations

Alnylam Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alnylam Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Alnylam Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Non Current Liabilities Total
Long Term Debt	+ 0.99	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.98	Total Assets
Property Plant Equipment	+ 0.98	Property Plant And Equipment Net

Property Plant And Equipment Gross	- 0.99	Retained Earnings
Property Plant Equipment	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Assets
Total Current Assets	- 0.96	Retained Earnings
Total Liab	- 0.96	Retained Earnings
Short Term Investments	- 0.96	Retained Earnings